GM32165/GM/NIGMS NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1984	2
1985	2
1986	2
1987	1
1988	1
1989	1
1990	1
1991	1
1993	5
1994	7
1995	2
1996	6
1997	7
1998	8
1999	8
2000	7
2001	9
2002	6
2003	3
2004	9
2005	13
2006	15
2007	10
2008	8
2009	5
2010	12
2011	12
2012	12
2013	7
2014	5
2015	4
2024	0

1

Rearrangement reactions catalyzed by cytochrome P450s.

Ortiz de Montellano PR, Nelson SD. Ortiz de Montellano PR, et al. Arch Biochem Biophys. 2011 Mar 1;507(1):95-110. doi: 10.1016/j.abb.2010.10.016. Epub 2010 Oct 29. Arch Biochem Biophys. 2011. PMID: 20971058 Free PMC article. Review.

2

Interactions of cytochrome P450s with their ligands.

Conner KP, Woods CM, Atkins WM. Conner KP, et al. Arch Biochem Biophys. 2011 Mar 1;507(1):56-65. doi: 10.1016/j.abb.2010.10.006. Epub 2010 Oct 19. Arch Biochem Biophys. 2011. PMID: 20939998 Free PMC article. Review.

3

Mass spectrometry.

Burlingame AL, Baillie TA, Derrick PJ. Burlingame AL, et al. Anal Chem. 1986 Apr;58(5):165R-211R. doi: 10.1021/ac00296a015. Anal Chem. 1986. PMID: 3521386 Review. No abstract available.

4

Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury.

Nelson SD. Nelson SD. Drug Metab Rev. 1995;27(1-2):147-77. doi: 10.3109/03602539509029821. Drug Metab Rev. 1995. PMID: 7641574 Review.

5

Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.

Rettie AE, Jones JP. Rettie AE, et al. Annu Rev Pharmacol Toxicol. 2005;45:477-94. doi: 10.1146/annurev.pharmtox.45.120403.095821. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822186 Review.

6

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.

Totah RA, Rettie AE. Totah RA, et al. Clin Pharmacol Ther. 2005 May;77(5):341-52. doi: 10.1016/j.clpt.2004.12.267. Clin Pharmacol Ther. 2005. PMID: 15900280 Review.

7

Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.

Ho HK, Chan JC, Hardy KD, Chan EC. Ho HK, et al. Drug Metab Rev. 2015 Feb;47(1):21-8. doi: 10.3109/03602532.2014.1003648. Epub 2015 Feb 2. Drug Metab Rev. 2015. PMID: 25639891 Free PMC article. Review.

8

In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.

Lutz JD, Isoherranen N. Lutz JD, et al. Expert Opin Drug Metab Toxicol. 2012 Apr;8(4):449-66. doi: 10.1517/17425255.2012.667801. Epub 2012 Mar 3. Expert Opin Drug Metab Toxicol. 2012. PMID: 22384784 Review.

9

Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.

Lutz JD, Fujioka Y, Isoherranen N. Lutz JD, et al. Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1095-109. doi: 10.1517/17425255.2010.497487. Expert Opin Drug Metab Toxicol. 2010. PMID: 20557268 Free PMC article. Review.

10

Developmental expression of human hepatic CYP2C9 and CYP2C19.

Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Koukouritaki SB, et al. J Pharmacol Exp Ther. 2004 Mar;308(3):965-74. doi: 10.1124/jpet.103.060137. Epub 2003 Nov 21. J Pharmacol Exp Ther. 2004. PMID: 14634042

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

176 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year